Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health benefits.

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...